Irvine, California – May 12, 2015. Harbor MedTech, Inc., a fully integrated and diversified tissue regeneration company, announced today that it had received confirmation from Medicare Administrative Contractor, Novitas Solutions, Inc., that the Company’s flagship product, Architect® has been approved for coverage when applied in the hospital outpatient and ambulatory surgery center settings. The coverage of Architect by Novitas in Local Coverage Determination (LCD) L27549 is effective immediately for 2 of the 12 Medicare jurisdictions, including the District of Columbia plus 11 states (Arkansas, Louisiana, Mississippi, Colorado, Texas, Oklahoma, New Mexico, Pennsylvania, New Jersey, Maryland, and Delaware.)

 

Architect is a unique extracellular collagen matrix (“ECM”) cleared by the FDA for use as a skin substitute to help manage the treatment of partial or full thickness skin wounds, including diabetic ulcers, venous ulcers, pressure ulcers/sores, trauma and surgical wounds. ECMs are used as “skin substitutes” because of their important tissue regeneration properties. Unfortunately, ECMs are susceptible to rapid degradation in serious or chronic skin wounds. Engineered from Harbor’s patented BriDGE® technology, Architect is the only stabilized ECM that requires only one application to the wound.

“We are extremely pleased that Architect is now available for treating Medicare patients in outpatient clinics and ambulatory care facilities,” said Jerry Mezger, President and CEO of Harbor. “Not only has Architect proven to be one of the most effective skin substitutes, it is also the most cost effective skin substitute treatment. Cost containment has become a very high priority in today’s healthcare system.”
For more information about Harbor MedTech and Architect, please contact Customer Support:

Telephone: 949.679.4800 x200
Facsimile: 949.679.1086
Email: support@harbormedtech.com

 

Architect® and BriDGE® are registered trademarks of Harbor MedTech, Inc.